Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Novel α7β2-Nicotinic Acetylcholine Receptor Subtype Is Expressed in Mouse and Human Basal Forebrain: Biochemical and Pharmacological Characterization

Milena Moretti, Michele Zoli, Andrew A. George, Ronald J. Lukas, Francesco Pistillo, Uwe Maskos, Paul Whiteaker and Cecilia Gotti
Molecular Pharmacology September 2014, 86 (3) 306-317; DOI: https://doi.org/10.1124/mol.114.093377
Milena Moretti
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Zoli
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew A. George
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald J. Lukas
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Pistillo
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Maskos
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Whiteaker
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecilia Gotti
CNR Institute of Neuroscience, Biometra University of Milan, Milan, Italy (M.M., F.P., C.G.); Section of Physiology and Neurosciences, Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (M.Z.); Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (A.A.G., R.J.L., P.W.); and Centre National de la Recherche Scientifique, Unité Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France (U.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

We examined α7β2-nicotinic acetylcholine receptor (α7β2-nAChR) expression in mammalian brain and compared pharmacological profiles of homomeric α7-nAChRs and α7β2-nAChRs. α-Bungarotoxin affinity purification or immunoprecipitation with anti-α7 subunit antibodies (Abs) was used to isolate nAChRs containing α7 subunits from mouse or human brain samples. α7β2-nAChRs were detected in forebrain, but not other tested regions, from both species, based on Western blot analysis of isolates using β2 subunit–specific Abs. Ab specificity was confirmed in control studies using subunit-null mutant mice or cell lines heterologously expressing specific human nAChR subtypes and subunits. Functional expression in Xenopus oocytes of concatenated pentameric (α7)5-, (α7)4(β2)1-, and (α7)3(β2)2-nAChRs was confirmed using two-electrode voltage clamp recording of responses to nicotinic ligands. Importantly, pharmacological profiles were indistinguishable for concatenated (α7)5-nAChRs or for homomeric α7-nAChRs constituted from unlinked α7 subunits. Pharmacological profiles were similar for (α7)5-, (α7)4(β2)1-, and (α7)3(β2)2-nAChRs except for diminished efficacy of nicotine (normalized to acetylcholine efficacy) at α7β2- versus α7-nAChRs. This study represents the first direct confirmation of α7β2-nAChR expression in human and mouse forebrain, supporting previous mouse studies that suggested relevance of α7β2-nAChRs in Alzheimer disease etiopathogenesis. These data also indicate that α7β2-nAChR subunit isoforms with different α7/β2 subunit ratios have similar pharmacological profiles to each other and to α7 homopentameric nAChRs. This supports the hypothesis that α7β2-nAChR agonist activation predominantly or entirely reflects binding to α7/α7 subunit interface sites.

Footnotes

    • Received April 22, 2014.
    • Accepted July 7, 2014.
  • M.M., M.Z., and A.A.G. contributed equally to this work; and P.W. and C.G. contributed equally to this work and are joint corresponding authors.

  • This research was supported by the European Union Seventh Framework Programme [Grant HEALTH-F2-2008-20208 (to C.G. and M.Z.)], CNR Research Project on Aging, Regione Lombardia Project NUTEC [Grant 30263049], Italian Ministry of Health [Grant RF2009-1549619 (to M.Z.)], and the National Institutes of Health National Institute on Drug Abuse [Grant R21-DA026627], and Barrow Neurologic Foundation (to P.W.). The Newcastle Brain Tissue Resource is supported by the Research Councils UK Medical Research Council [Grant G0400074], National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne National Health Service Foundation Trust, Newcastle University, and the Alzheimer’s Society and Alzheimer’s Research Trust [Brains for Dementia Research Project].

  • dx.doi.org/10.1124/mol.114.093377.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (3)
Molecular Pharmacology
Vol. 86, Issue 3
1 Sep 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Novel α7β2-Nicotinic Acetylcholine Receptor Subtype Is Expressed in Mouse and Human Basal Forebrain: Biochemical and Pharmacological Characterization
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Human α7β2-nAChR Human Expression and Functional Pharmacology

Milena Moretti, Michele Zoli, Andrew A. George, Ronald J. Lukas, Francesco Pistillo, Uwe Maskos, Paul Whiteaker and Cecilia Gotti
Molecular Pharmacology September 1, 2014, 86 (3) 306-317; DOI: https://doi.org/10.1124/mol.114.093377

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Human α7β2-nAChR Human Expression and Functional Pharmacology

Milena Moretti, Michele Zoli, Andrew A. George, Ronald J. Lukas, Francesco Pistillo, Uwe Maskos, Paul Whiteaker and Cecilia Gotti
Molecular Pharmacology September 1, 2014, 86 (3) 306-317; DOI: https://doi.org/10.1124/mol.114.093377
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics